Ensysce Biosciences Inc. (NASDAQ:ENSC) went down by -5.93% from its latest closing price compared to the recent 1-year high of $7.00. The company’s stock price has collected -35.20% of loss in the last five trading sessions.
Is It Worth Investing in Ensysce Biosciences Inc. (NASDAQ :ENSC) Right Now?
Ensysce Biosciences Inc. (NASDAQ:ENSC) scored a price-to-earnings ratio above its average ratio, recording 0.50 x from its present earnings ratio. Plus, the 36-month beta value for ENSC is at -0.11.
Today, the average trading volume of ENSC was 1.63M shares.
ENSC’s Market Performance
ENSC stocks went down by -35.20% for the week, with a monthly drop of -45.35% and a quarterly performance of -51.01%, while its annual performance rate touched -94.81%. The volatility ratio for the week stands at 19.95% while the volatility levels for the past 30 days are set at 14.38% for Ensysce Biosciences Inc. The simple moving average for the period of the last 20 days is -39.41% for ENSC stocks with a simple moving average of -82.93% for the last 200 days.
ENSC Trading at -51.68% from the 50-Day Moving Average
After a stumble in the market that brought ENSC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -96.81% of loss for the given period.
Volatility was left at 14.38%, however, over the last 30 days, the volatility rate increased by 19.95%, as shares sank -49.78% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -65.08% lower at present.
During the last 5 trading sessions, ENSC fell by -35.20%, which changed the moving average for the period of 200-days by -83.44% in comparison to the 20-day moving average, which settled at $0.3578. In addition, Ensysce Biosciences Inc. saw -95.24% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at ENSC starting from Kirkpatrick Lynn, who purchase 27,000 shares at the price of $0.53 back on May 26. After this action, Kirkpatrick Lynn now owns 381,851 shares of Ensysce Biosciences Inc., valued at $14,216 using the latest closing price.
Kirkpatrick Lynn, the Chief Executive Officer of Ensysce Biosciences Inc., purchase 70,000 shares at $0.49 during a trade that took place back on May 25, which means that Kirkpatrick Lynn is holding 354,851 shares at $34,083 based on the most recent closing price.
Stock Fundamentals for ENSC
Current profitability levels for the company are sitting at:
- -562.71 for the present operating margin
- +100.00 for the gross margin
The net margin for Ensysce Biosciences Inc. stands at -823.62. Equity return is now at value 107.10, with 22.50 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 0.95.